Evidence map›Paper›PMID 40313548›Full record

ArticleFrontiers in medicine2025

Qiujuan Li, Chenbing Wu, Kangshuai Zhang, Ziyi Zhou, Jing Li, Jie Bai, Jun Cao, Xiaoxia Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qiujuan Li *Department of Experimental Teaching Center of Public Health, Dalian Medical University, Dalian, China.
Chenbing Wu *Department of Experimental Teaching Center of Public Health, Dalian Medical University, Dalian, China.
Kangshuai ZhangDepartment of Experimental Teaching Center of Public Health, Dalian Medical University, Dalian, China.
Ziyi ZhouDepartment of Experimental Teaching Center of Public Health, Dalian Medical University, Dalian, China.
Jing LiDepartment of Pathology and Forensic Medicine, Dalian Medical University, Dalian, China.
Jie BaiDepartment of Experimental Teaching Center of Public Health, Dalian Medical University, Dalian, China.
Jun CaoDepartment of Occupational and Environmental Health, Dalian Medical University, Dalian, China.
Xiaoxia ShiDepartment of Experimental Teaching Center of Public Health, Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-tuberculosis drug-induced liver injury (ATB-DILI), caused by first-line anti-tuberculosis (anti-TB) drugs, disrupts treatment and increases the risk of drug resistance. The gut microbiota and intestinal barrier integrity play key roles in ATB-DILI susceptibility through the liver-gut axis. Probiotics, such as

Indexed as

anti-tuberculosis drugsBacteroides fragilis 839intestinal barrierliver injuryLPS/TLRs/NF-κB pathway

Identifiers

PMID40313548
PMCPMC12043568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.